IMC Chicago
ASND icon

IMC Chicago’s Ascendis Pharma A/S ASND Stock Holding History

IMC Chicago’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
47,200
+21,900
+87% +$4.91M ﹤0.01% 1207
2025
Q4 		$5.39M Buy
25,300
+6,100
+32% +$1.26M ﹤0.01% 1683
2025
Q3 		$3.82M Buy
+19,200
New +$3.58M ﹤0.01% 1762

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

IMC Chicago's ASND Position: Q1 2026 in Review

IMC Chicago sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 113,682 shares — an estimated $25.5M sold.

IMC Chicago first reported a position in ASND in Q4 2025 and held it in 1 quarter. The position peaked at $24.2M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • IMC Chicago reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • IMC Chicago sold 113,682 Ascendis Pharma A/S shares in Q1 2026, an estimated $25.5M.
  • IMC Chicago first reported a position in Ascendis Pharma A/S in Q4 2025 and held it in 1 quarter.
  • IMC Chicago's Ascendis Pharma A/S position peaked at $24.2M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.